Post-Traumatic Stress Disorder (PTSD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Post Traumatic Stress Disorder Pipeline Drugs Market Overview
Post-traumatic stress disorder (PTSD) is a mental health condition that’s triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares, and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety, and cognitive therapy.
The post-traumatic stress disorder (PTSD) drugs in development market research report provides an overview of the post-traumatic stress disorder (PTSD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for PTSD, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for PTSD and features dormant and discontinued projects.
What are the targets of the PTSD pipeline drugs market?
Some of the targets of the PTSD pipeline drugs market are 5-Hydroxytryptamine Receptor 2A, Cannabinoid Receptor 1, Cannabinoid Receptor 2, 5-Hydroxytryptamine Receptor 1A, Glutamate Ionotropic Receptor NMDA Type Subunit, Fatty Acid Amide Hydrolase, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Sodium Dependent Dopamine Transporter, Sodium Dependent Serotonin Transporter, and Sodium Dependent Noradrenaline Transporter.
PTSD pipeline drugs market, by targets
For more target insights, download a free report sample
What are the mechanisms of action of the PTSD pipeline drugs market?
Some of the mechanisms of action of the PTSD pipeline drugs market are 5-Hydroxytryptamine Receptor 2A Agonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, Fatty Acid Amide Hydrolase Inhibitor, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, 5-Hydroxytryptamine Receptor 2A Antagonist, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist, Sodium Dependent Dopamine Transporter Inhibitor, and Sodium Dependent Noradrenaline Transporter Inhibitor.
PTSD pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What are the routes of administration in the PTSD pipeline drugs market?
The routes of administration in the PTSD pipeline drugs market are oral, nasal, intravenous, sublingual, intramuscular, intradermal, subcutaneous, and transdermal.
PTSD pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
What are the molecule types in the PTSD pipeline drugs market?
The molecule types in the PTSD pipeline drugs market are small molecule, peptide, synthetic peptide, and inactivated vaccine.
PTSD pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Which are the key companies in the PTSD pipeline drugs market?
Some of the key companies in the PTSD pipeline drugs market are Tonix Pharmaceuticals Holding Corp, Alto Neuroscience Inc, Addex Therapeutics Ltd, Allied Corp, Anagin Inc, Artelo Biosciences Inc, Exxel Pharma Inc, H. Lundbeck AS, Jazz Pharmaceuticals Plc, and Johnson & Johnson.
PTSD pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report scope
| Targets | 5-Hydroxytryptamine Receptor 2A, Cannabinoid Receptor 1, Cannabinoid Receptor 2, 5-Hydroxytryptamine Receptor 1A, Glutamate Ionotropic Receptor NMDA Type Subunit, Fatty Acid Amide Hydrolase, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Sodium Dependent Dopamine Transporter, Sodium Dependent Serotonin Transporter, and Sodium Dependent Noradrenaline Transporter |
| Mechanisms of Action | 5-Hydroxytryptamine Receptor 2A Agonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, Fatty Acid Amide Hydrolase Inhibitor, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, 5-Hydroxytryptamine Receptor 2A Antagonist, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist, Sodium Dependent Dopamine Transporter Inhibitor, and Sodium Dependent Noradrenaline Transporter Inhibitor |
| Routes of Administration | Oral, Nasal, Intravenous, Sublingual, Intramuscular, Intradermal, Subcutaneous, and Transdermal |
| Molecule Types | Small Molecule, Peptide, Synthetic Peptide, and Inactivated Vaccine |
| Key Companies | Tonix Pharmaceuticals Holding Corp, Alto Neuroscience Inc, Addex Therapeutics Ltd, Allied Corp, Anagin Inc, Artelo Biosciences Inc, Exxel Pharma Inc, H. Lundbeck AS, Jazz Pharmaceuticals Plc, and Johnson & Johnson |
This report provides:
- A snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- Reviews of pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- Evaluation of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Actinogen Medical Ltd
Addex Therapeutics Ltd
Aision Biotechnologies Inc
Algernon Pharmaceuticals Inc
Allied Corp
Alto Neuroscience Inc
Alzamend Neuro Inc
Amorsa Therapeutics Inc
Anagin Inc
Ananda Scientific Inc
Apex Labs Ltd
Aptinyx Inc
ARMGO Pharma Inc
Artelo Biosciences Inc
Avicanna Inc
Better Life Pharmaceuticals Inc
Bionomics Ltd
Bionorica SE
BioXcel Therapeutics Inc
Boehringer Ingelheim International GmbH
Braxia Scientific Corp
Bright Minds Biosciences Inc
Cannabis Science Inc
Chronos Therapeutics Ltd
Compass Pathways Plc
Corcept Therapeutics Inc
Delix Therapeutics Inc
Eli Lilly and Co
Embera NeuroTherapeutics Inc
EmpathBio
Endosane Pharmaceuticals GmbH
Enveric Biosciences Inc
EpiVario Inc
Evecxia Therapeutics Inc
Exxel Pharma Inc
H. Lundbeck AS
Halucenex Life Sciences Inc
Immodulon Therapeutics Ltd
INVENT Pharmaceuticals Inc
iX Biopharma Ltd
Jazz Pharmaceuticals Plc
Johnson & Johnson
Kdac Therapeutics Inc
Lactocore Inc
Lennham Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
Mindstate Design Labs
Mydecine Innovations Group Inc
Nanomerics Ltd
Neuritek Therapeutics Ltd
NeuroNascent Inc
NeuroPharm Inc
Neurovation Labs Inc
NRX Pharmaceuticals Inc
Omeros Corp
One World Cannabis Ltd
Otsuka Pharmaceutical Co Ltd
PharmaTher Holdings Ltd
Praxis Precision Medicines Inc
Protagenic Therapeutics Inc
Psy Therapeutics Inc
PsyBio Therapeutics Corp
Sage Therapeutics Inc
Sanofi
Scientus Pharma Inc
Seelos Therapeutics, Inc.
Synendos Therapeutics AG
Tonix Pharmaceuticals Holding Corp
Virpax Pharmaceuticals Inc
VistaGen Therapeutics Inc
Wake Network Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the PTSD pipeline drugs market?
Some of the targets of the PTSD pipeline drugs market are 5-Hydroxytryptamine Receptor 2A, Cannabinoid Receptor 1, Cannabinoid Receptor 2, 5-Hydroxytryptamine Receptor 1A, Glutamate Ionotropic Receptor NMDA Type Subunit, Fatty Acid Amide Hydrolase, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Sodium Dependent Dopamine Transporter, Sodium Dependent Serotonin Transporter, and Sodium Dependent Noradrenaline Transporter.
-
What are the mechanisms of action of the PTSD pipeline drugs market?
Some of the mechanisms of action of the PTSD pipeline drugs market are 5-Hydroxytryptamine Receptor 2A Agonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, Fatty Acid Amide Hydrolase Inhibitor, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, 5-Hydroxytryptamine Receptor 2A Antagonist, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist, Sodium Dependent Dopamine Transporter Inhibitor, and Sodium Dependent Noradrenaline Transporter Inhibitor.
-
What are the routes of administration in the PTSD pipeline drugs market?
The routes of administration in the PTSD pipeline drugs market are oral, nasal, intravenous, sublingual, intramuscular, intradermal, subcutaneous, and transdermal.
-
What are the molecule types in the PTSD pipeline drugs market?
The molecule types in the PTSD pipeline drugs market are small molecule, peptide, synthetic peptide, and inactivated vaccine.
-
Which are the key companies in the PTSD pipeline drugs market?
Some of the key companies in the PTSD pipeline drugs market are Tonix Pharmaceuticals Holding Corp, Alto Neuroscience Inc, Addex Therapeutics Ltd, Allied Corp, Anagin Inc, Artelo Biosciences Inc, Exxel Pharma Inc, H. Lundbeck AS, Jazz Pharmaceuticals Plc, and Johnson & Johnson.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Central Nervous System reports